Cargando…
Behçet's Uveitis
Behçet's disease is a multisystem inflammatory disorder that is most common in countries along the ancient “Silk Road”. The eye is the most commonly involved vital organ in Behçet's patients and the typical form of involvement is a relapsing remitting panuveitis and retinal vasculitis. Uve...
Autor principal: | |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855662/ https://www.ncbi.nlm.nih.gov/pubmed/20404988 http://dx.doi.org/10.4103/0974-9233.58425 |
_version_ | 1782180201859383296 |
---|---|
author | Tugal-Tutkun, Ilknur |
author_facet | Tugal-Tutkun, Ilknur |
author_sort | Tugal-Tutkun, Ilknur |
collection | PubMed |
description | Behçet's disease is a multisystem inflammatory disorder that is most common in countries along the ancient “Silk Road”. The eye is the most commonly involved vital organ in Behçet's patients and the typical form of involvement is a relapsing remitting panuveitis and retinal vasculitis. Uveitis is the initial manifestation of the disease in 10-15% of the patients. Anterior uveitis is always nongranulomatous. Diffuse vitritis, retinal infiltrates, sheathing of predominantly retinal veins, and occlusive vasculitis are the typical signs of posterior segment inflammation. Spontaneous resolution of acute inflammatory signs is a diagnostic feature. Fundus fluorescein angiography is the gold standard in monitoring inflammatory activity. Laser flare photometry is a useful noninvasive tool since flare readings correlate with fluorescein angiographic leakage. The most common complications are cataract, maculopathy, and optic atrophy. Male patients have a more severe disease course and worse visual prognosis. Immunomodulatory therapy is indicated in all patients with posterior segment involvement. Corticosteroids combined with azathioprine and/or cyclosporine is used initially. Biologic agents, including interferon alfa and infliximab, are used in resistant cases. Visual prognosis has improved in recent years with an earlier and more aggressive use of immunomodulatory therapy and the use of biologic agents in resistant cases. |
format | Text |
id | pubmed-2855662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-28556622010-04-19 Behçet's Uveitis Tugal-Tutkun, Ilknur Middle East Afr J Ophthalmol Symposium - Uveitis Update Behçet's disease is a multisystem inflammatory disorder that is most common in countries along the ancient “Silk Road”. The eye is the most commonly involved vital organ in Behçet's patients and the typical form of involvement is a relapsing remitting panuveitis and retinal vasculitis. Uveitis is the initial manifestation of the disease in 10-15% of the patients. Anterior uveitis is always nongranulomatous. Diffuse vitritis, retinal infiltrates, sheathing of predominantly retinal veins, and occlusive vasculitis are the typical signs of posterior segment inflammation. Spontaneous resolution of acute inflammatory signs is a diagnostic feature. Fundus fluorescein angiography is the gold standard in monitoring inflammatory activity. Laser flare photometry is a useful noninvasive tool since flare readings correlate with fluorescein angiographic leakage. The most common complications are cataract, maculopathy, and optic atrophy. Male patients have a more severe disease course and worse visual prognosis. Immunomodulatory therapy is indicated in all patients with posterior segment involvement. Corticosteroids combined with azathioprine and/or cyclosporine is used initially. Biologic agents, including interferon alfa and infliximab, are used in resistant cases. Visual prognosis has improved in recent years with an earlier and more aggressive use of immunomodulatory therapy and the use of biologic agents in resistant cases. Medknow Publications 2009 /pmc/articles/PMC2855662/ /pubmed/20404988 http://dx.doi.org/10.4103/0974-9233.58425 Text en © Middle East African Journal of Ophthalmology http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Symposium - Uveitis Update Tugal-Tutkun, Ilknur Behçet's Uveitis |
title | Behçet's Uveitis |
title_full | Behçet's Uveitis |
title_fullStr | Behçet's Uveitis |
title_full_unstemmed | Behçet's Uveitis |
title_short | Behçet's Uveitis |
title_sort | behçet's uveitis |
topic | Symposium - Uveitis Update |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855662/ https://www.ncbi.nlm.nih.gov/pubmed/20404988 http://dx.doi.org/10.4103/0974-9233.58425 |
work_keys_str_mv | AT tugaltutkunilknur behcetsuveitis |